8-K: Propanc Biopharma Faces Nasdaq Delisting Warning

Propanc Biopharma received a notice from Nasdaq indicating non-compliance with the minimum bid price requirement, with potential delisting on November 2, 2026, unless an appeal is filed.

Summary

• Propanc Biopharma, Inc. received a written notice from Nasdaq on October 23, 2026, stating it is not in compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market.
• The company's common stock closing bid price was below $1.00 for 30 consecutive business days prior to October 21, 2026.
• Unlike typical cases, Propanc is not eligible for the standard 180-day compliance period because it executed a reverse stock split within the prior year.
• The company's securities are scheduled for delisting on November 2, 2026, unless an appeal is requested by October 30, 2026.
• Propanc Biopharma intends to appeal the delisting determination, believing it has rectified the deficiency.
• A successful appeal would stay the delisting, allowing the securities to remain listed pending the Nasdaq hearings panel's decision.
• The receipt of this notice does not impact the company's business operations or SEC reporting requirements.
• Potential consequences of delisting include reduced liquidity, lower market price, difficulty in raising equity financing, and impaired ability to offer equity incentives.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative development due to the notice of potential delisting from Nasdaq, despite the company's intent to appeal.

Positives

• The company intends to appeal the delisting notice, indicating a proactive approach to resolving the issue.
• Propanc Biopharma believes it has already cured the deficiency in the minimum bid price.
• The company's business operations and SEC reporting requirements remain unaffected by the notice.

Negatives

• Received a written notice from Nasdaq on October 23, 2026, for failing to meet the $1.00 minimum bid price requirement.
• The company's common stock closing bid price was below $1.00 for 30 consecutive business days ending October 21, 2026.
• Ineligible for the standard 180-day compliance period due to a prior reverse stock split within the last year.
• Securities are slated for delisting from The Nasdaq Capital Market on November 2, 2026, if no appeal is filed.
• Potential negative impacts of delisting include reduced stock liquidity and market price.
• Delisting could hinder the company's ability to raise equity financing and access public capital markets.
• Delisting may impair the company's capacity to offer equity incentives to employees.

Risks

• The possibility that Nasdaq may deny the company's appeal, leading to delisting.
• If delisted, the company may experience reduced liquidity and market price for its common stock.
• Delisting could negatively impact the company's ability to raise equity financing.
• Inability to access public capital markets through registration statements if delisted.
• Potential for violations of additional Nasdaq listing rules in the future.
• Material delays in the company's financial reporting could exacerbate issues.
• Factors detailed in the Risk Factors section of the company's SEC filings could materialize.

Future Outlook

The company is focused on appealing the Nasdaq delisting notice and believes it has addressed the minimum bid price deficiency. The outcome of the appeal will determine the future listing status on Nasdaq.

Management Comments

• The Company intends to request this appeal by the October 30, 2026 deadline as the Company believes it has cured the Bid Price Requirement deficiency subsequent to the receipt and date of the Notice.

Industry Context

StockSavvy.ai notes that Nasdaq's minimum bid price rule is a common compliance hurdle for smaller-cap companies. Companies often resort to reverse stock splits to meet this requirement, but as seen here, this action can sometimes preclude them from standard compliance grace periods.

Stakeholder Impact

• Shareholders may experience reduced liquidity and a lower market price for their shares.
• The company's ability to attract and retain investors may be diminished.
• Employees may be impacted by the company's reduced ability to provide equity incentives.

Next Steps

• Request an appeal of the delisting determination by October 30, 2026.
• Await the decision from the Nasdaq hearings panel regarding the appeal.
• Continue business operations and SEC reporting requirements.

Key Dates

Recommendation

While the delisting notice is a significant negative, the company's intent to appeal and its belief in having cured the deficiency suggest a potential for resolution. A 'hold' recommendation reflects the uncertainty and the need to await the outcome of the appeal process before making a more definitive investment decision.

Keywords

Nasdaq delisting, minimum bid price, listing compliance, reverse stock split, appeal process, equity financing, stock liquidity